Loading...
XSTOONCO
Market cap28mUSD
Dec 23, Last price  
1.48SEK
1D
-1.99%
1Q
-29.19%
IPO
-96.47%
Name

Oncopeptides AB

Chart & Performance

D1W1MN
XSTO:ONCO chart
P/E
—
P/S
8.88
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.19%
Rev. gr., 5y
0.00%
Revenues
35m
+321.54%
0000000118,295,0008,355,00035,220,000
Net income
-249m
L-26.29%
-33,093,978-53,341,000-114,445,869-247,620,000-419,449,000-740,705,000-1,594,693,000-1,430,318,000-337,951,000-249,111,000
CFO
-279m
L-33.53%
-31,438,604-52,808,000-104,262,104-271,497,000-333,727,000-690,566,000-1,296,509,000-1,516,391,000-420,509,000-279,493,000
Earnings
Feb 27, 2025

Profile

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
URL
https://www.oncopeptides.se/
IPO date
Feb 22, 2017
Employees
63
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
35,220
321.54%
8,355
-92.94%
118,295
 
Cost of revenue
294,348
359,858
1,606,852
Unusual Expense (Income)
NOPBT
(259,128)
(351,503)
(1,488,557)
NOPBT Margin
Operating Taxes
664
271
8,946
Tax Rate
NOPAT
(259,792)
(351,774)
(1,497,503)
Net income
(249,111)
-26.29%
(337,951)
-76.37%
(1,430,318)
-10.31%
Dividends
Dividend yield
Proceeds from repurchase of equity
(24)
407,944
1,049,435
BB yield
0.00%
-40.79%
-165.93%
Debt
Debt current
5,999
10,987
Long-term debt
145,825
13,085
17,399
Deferred revenue
Other long-term liabilities
10,509
1,815
13
Net debt
(27,614)
(326,282)
(334,652)
Cash flow
Cash from operating activities
(279,493)
(420,509)
(1,516,391)
CAPEX
(116)
(2,507)
(339)
Cash from investing activities
(116)
(2,507)
(339)
Cash from financing activities
106,889
392,402
1,034,030
FCF
(273,980)
(347,468)
(1,483,917)
Balance
Cash
173,439
344,515
362,187
Long term investments
851
851
Excess cash
171,678
344,948
357,123
Stockholders' equity
(5,355,476)
(5,105,935)
(4,770,097)
Invested Capital
5,548,921
5,404,807
4,988,146
ROIC
ROCE
EV
Common stock shares outstanding
126,836
82,320
75,292
Price
7.66
-36.95%
12.15
44.64%
8.40
-95.05%
Market cap
971,561
-2.86%
1,000,188
58.14%
632,453
-94.02%
EV
943,947
676,203
298,719
EBITDA
(248,088)
(334,342)
(1,473,563)
EV/EBITDA
Interest
5,785
883
948
Interest/NOPBT